The impact of tumor hypoxia on the clinical efficacy of anti-PD-1 mAb treatment in recurrent/metastatic HNSCC patients (R/M).
Dan P. Zandberg(University of Pittsburgh Medical Center), Greg M. Delgoffe(University of Pittsburgh), Heath D. Skinner(University of Pittsburgh), Umamaheswar Duvvuri(City University of New York), Maria A. Velez(University of Pittsburgh Medical Center), James Ohr(University of Pittsburgh), Simion I. Chiosea(University of Pittsburgh), Marci L. Nilsen(University of Pittsburgh), Robert L. Ferris(University of Pittsburgh), Ashley V. Menk(UPMC Hillman Cancer Center), David A. Clump(West Virginia University), Angen Liu(University of Pittsburgh)
Cited by 10
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2
|Nature Immunology|2011|1.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688